

## Special Issue

# The Advances of Cold Plasma in the Biomedicines

### Message from the Guest Editor

Plasma medicine, which started when cold plasma was applied to bacteria and cells, has made much progress for nearly 20 years. The scope of plasma research is expanding from just killing pathogens and cancer cells to tissue regeneration and selective cancer cell death. Among the numerous constituents of plasma, studies on which ones have medical functions and the mechanisms by which plasma-induced biomedical phenomena depend on are being actively conducted. Plasma medical devices are being developed based on these studies, and it is expected that various plasma medical devices will be introduced to the medical market in the near future.

In the current research climate, this Special Issue calls for advanced plasma medicine research results by explaining not only various life phenomena induced by plasma, but also cellular or histologic mechanisms. The scope of the research subject is limited to bacteria living in animals, animal cells and tissues, and biomaterials that can be inserted into the human body. Experimental as well as review papers consistent with this research topic are welcome.

---

### Guest Editor

Prof. Dr. Gyoocheon Kim  
Department of Oral Anatomy, School of Dentistry, Pusan National University, Yangsan 50612, Korea

---

### Deadline for manuscript submissions

closed (15 March 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/85792](https://mdpi.com/si/85792)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).